Scribe Therapeutics Inc.
CRISPR-based gene editing therapeutics for disease treatment
- Sector
- Biotech
- Headquarters
- Berkeley, CA
- Founded
- 2017
- Latest Form D
- $100M, Apr 2021
- Total capital
- $100M
- Federal grants
- $300K
- 2 awards · 2019
- Rank in peer group#62 of 392
- Private capital raised
- $100M
- 1 Form D · last Apr 2021
- 67 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 29 pending · first 2022
- Rank in peer group#12 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$100M
- Federal grantHealth and Human S · Phase I · Genome editing using a novel CRISPR protein$150K
- Federal grantHealth and Human S · Phase I · Development of CRISPR-Cas guideRNA screening platform for allele-specific reduction of mutant Huntingtin protein$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
26months
from Scribe Therapeutics Inc.’s first federal award to its first private round.
- First federal award · Feb 2019
- Health and Human S · $150K
- First Form D · Apr 2021
- $100M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#62 · top 16%
- Granted patents#12 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Benjamin OakesResearcherExecutive Officer, DirectorLinked by $150K in grants as PI
- Behzad AghazadehDirectorNamed in SEC Form D filings
- Carl GordonDirectorNamed in SEC Form D filings
- Vijay PandeDirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 40- PendingRepressor Fusion Protein SystemsUSPTOApplication 19343818
- PendingEngineered Class 2, Type V Repressor SystemsUSPTOApplication 19532260
- PendingCompositions And Methods For The Targeting Of LpaUSPTOApplication 19343806
Show all 40 patent records
- Repressor Fusion Protein SystemsAug 20, 2026 · Application 19343818Pending
- Engineered Class 2, Type V Repressor SystemsAug 6, 2026 · Application 19532260Pending
- Compositions And Methods For The Targeting Of LpaJun 4, 2026 · Application 19343806Pending
- Compositions And Methods For The Targeting Of PCSK9Apr 7, 2026 · US 12,594,349Granted
- Engineered Guide ScaffoldsFeb 24, 2026 · US 12,559,743Granted
- Compositions And Methods For The Targeting Of PCSK9Feb 17, 2026 · US 12,551,573Granted
- Compositions And Methods For Use In ImmunotherapyFeb 17, 2026 · US 12,551,560Granted
- Engineered Class 2, Type V Repressor SystemsFeb 17, 2026 · US 12,553,037Granted
- Aav Vectors For Gene EditingNov 27, 2025 · Application 18872584Pending
- Engineered Class 2 Type V Crispr SystemsOct 30, 2025 · Application 18869765Pending
- Catalytically Dead Engineered ProteinsMay 1, 2025 · Application 18909093Pending
- Gene Editing PairsFeb 6, 2025 · Application 18778393Pending
- Methods Of Editing With Engineered Class 2 Type V Crispr SystemsJan 9, 2025 · Application 18663845Pending
- Engineered Class 2 Type V Crispr SystemsDec 10, 2024 · US 12,163,125Granted
- Engineered Casx Repressor SystemsNov 28, 2024 · Application 18693062Pending
- Self-inactivating Vectors For Gene EditingOct 31, 2024 · Application 18608127Pending
- COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72Sep 19, 2024 · Application 17932798Pending
- Guide ScaffoldsSep 10, 2024 · US 12,084,692Granted
- Compositions Of Glycoprotein ParticlesJun 27, 2024 · Application 18568029Pending
- Particle Delivery SystemsMay 7, 2024 · US 11,976,277Granted
- Compositions And Methods For The Targeting Of SOD1Mar 28, 2024 · Application 18168426Pending
- Compositions And Methods For The Targeting Of PTBP1Mar 28, 2024 · Application 18255182Pending
- Aav Vectors For Gene EditingFeb 1, 2024 · Application 18266076Pending
- Compositions And Methods For The Targeting Of BCL11AJan 25, 2024 · Application 18255172Pending
- Engineered Class 2 Type V Crispr SystemsJan 25, 2024 · Application 18039858Pending
- Compositions And Methods For The Targeting Of PCSK9Jun 1, 2023 · Application 17791130Pending
- Compositions And Methods For The Targeting Of SOD1Mar 28, 2023 · US 11,613,742Granted
- Compositions And Methods For The Targeting Of HttFeb 2, 2023 · Application 17829206Pending
- Compositions And Methods For The Targeting Of RhodopsinFeb 2, 2023 · Application 17780945Pending
- Engineered ProteinsJan 24, 2023 · US 11,560,555Granted
- Compositions And Methods For The Targeting Of RhodopsinDec 27, 2022 · US 11,535,835Granted
- Compositions And Methods For The Targeting Of SOD1Nov 3, 2022 · Application 17641426Pending
- Engineered Casx SystemsJul 14, 2022 · Application 17542219Pending
- Deep Mutational Evolution Of BiomoleculesJun 9, 2022 · Application 17542238Pending
- Optimized PolynucleotidesApplication 63585766Pending
- Compositions And Methods For The Targeting Of LpaApplication PCTUS2024022042Pending
- Particle Delivery SystemsApplication 19138063Pending
- Compositions And Methods For The Targeting Of Apolipoprotein C3Application 63719744Pending
- Particle Delivery SystemsApplication PCTUS2023084036Pending
- Compositions And Methods For The Targeting Of Apolipoprotein C3Application 63649154Pending
Related companies, and why
- ADVANTAGE THERAPEUTICS, INCSimilar federal contract value in Biotech · null in contracts
- ENVISAGENICS INCSimilar federal contract value in Biotech · null in contracts
- Quralis CorporationSimilar federal contract value in Biotech · null in contracts
- GENEVENTIV THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- BIOSYMETRICS, INC.Similar federal contract value in Biotech · null in contracts
- CYTEGEN CORPSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .